Biora Therapeutics, Inc. (NASDAQ:BIOR) Short Interest Update

Biora Therapeutics, Inc. (NASDAQ:BIOR) saw a large increase in short interest in October. As of October 31st, there was short interest totalling 201,800 shares, an increase of 43.3% from the October 15th total of 140,800 shares. Based on an average daily volume of 50,100 shares, the short-interest ratio is presently 4.0 days. Approximately 4.8% of the shares of the stock are short sold.

Biora Therapeutics Stock Down 10.9 %

NASDAQ BIOR traded down $0.26 on Friday, reaching $2.12. The company had a trading volume of 189,724 shares, compared to its average volume of 40,747. The firm’s 50 day moving average price is $4.73 and its 200 day moving average price is $6.04. Biora Therapeutics has a 12 month low of $2.03 and a 12 month high of $19.90. The stock has a market capitalization of $7.80 million, a PE ratio of -0.16 and a beta of 1.27.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $150.00 price objective on shares of Biora Therapeutics in a report on Tuesday, August 13th.

Biora Therapeutics Company Profile

Biora Therapeutics, Inc, a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases.